SEARCH:   Advanced

Blood, 1 March 2005, Vol. 105, No. 5, pp. 2175-2179. Prepublished online as a Blood First Edition Paper on September 21, 2004; DOI 10.1182/blood-2004-04-1554. This Article Full Text (PDF) All Versions of this Article: 2004-04-1554v1 105/5/2175    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hall, A. M Articles by Urbaniak, S. J Search for Related Content PubMed PubMed Citation Articles by Hall, A. M Articles by Urbaniak, S. J Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 27, 2004 Accepted September 16, 2004 Immune responses and tolerance to the RhD blood group protein in HLA-transgenic mice Andrew M Hall, Lindsay S Cairns, Daniel M Altmann, Robert N Barker, and Stanislaw J Urbaniak* Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom; Academic Transfusion Medicine Unit, Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom Human Disease Immunogenetics Group, Department of Infectious Diseases, Imperial College, London, United Kingdom * Corresponding author; email: s.j.urbaniak{at}abdn.ac.uk. RhD is a major blood group and the most important target antigen in hemolytic disease of the newborn (HDN). The aims were to establish a humanized mouse model of responses to the RhD protein, and to test whether these could be prevented by the induction of immune tolerance. Expression of an HLA-DR transgene was found to confer on mice the ability to respond to immunization with purified RhD protein. Synthetic peptides containing dominant helper T-cell epitopes, previously identified from studies of human alloimmunized donors, were administered to the nasal mucosa of transgenic mice prior to immunization with purified RhD protein. Treatment with each of the four dominant peptides, RhD52-66, RhD97-111, RhD117-131, or RhD177-191, inhibited T-cell priming and prevented antibody responses to the RhD protein. The ability to induce such active tolerance offers the prospect of peptide immunotherapy as a replacement for passive immune globulin in the prophylaxis of HDN. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. J. Anstee Red cell genotyping and the future of pretransfusion testing Blood, July 9, 2009; 114(2): 248 - 256. [Abstract] [Full Text] [PDF] H. Sukati, H. G. Watson, S. J. Urbaniak, and R. N. Barker Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura Blood, May 15, 2007; 109(10): 4528 - 4538. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020